Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 plus nab-paclitaxel versus nab-paclitaxel in second-line extensive-stage small cell lung cancer
ChiCTR2400092048Phase 4Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of evoximab and paclitaxel in small cell lung cancer (SCLC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
evoximabpaclitaxel
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400092048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092048.